Patents by Inventor Dmitry Dmitrievich Genkin

Dmitry Dmitrievich Genkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
    Patent number: 11905522
    Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: February 20, 2024
    Assignee: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • COMBINATION OF DEOXYRIBONUCLEASE ENZYME AND CELL THERAPIES FOR TREATMENT OF CANCER
    Publication number: 20240050476
    Abstract: The invention relates to methods for treatment of cancers utilizing a combination of a deoxyribonuclease enzyme and adoptive cell immunotherapy comprising cells expressing a chimeric antigen receptor (CAR) or a T cell receptor (TCR). In particular embodiments, the deoxyribonuclease enzyme can be given parenterally or encoded by a vector or secreted by a cell comprising TCR or CAR.
    Type: Application
    Filed: January 7, 2022
    Publication date: February 15, 2024
    Applicant: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS, Alexey Vyacheslavovich STEPANOV
  • Extracellular DNA as a therapeutic target in neurodegeneration
    Patent number: 11701410
    Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: July 18, 2023
    Assignee: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • TREATMENT OF DISEASES ASSOCIATED WITH PROTEIN MISFOLDING BY NERVOUS SYSTEM EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY
    Publication number: 20220241394
    Abstract: The invention relates to the nervous system-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of microbial and viral cell free DNA (cfDNA) accumulated in cerebrospinal fluid (CSF), brain and other parts of nervous system, with the use of such nervous-system specific delivery and/or expression for treatment of various diseases associated with protein misfolding.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 4, 2022
    Applicant: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS
  • ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
    Publication number: 20220018845
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: July 26, 2021
    Publication date: January 20, 2022
    Applicants: HESPERIX SA, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Alexander Gabibovich Gabibov, Richard A. Lerner, Alexey Anatolievich Belogurov, Jia Xie
  • Articles and methods directed to personalized therapy of cancer
    Patent number: 11215618
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: January 4, 2022
    Assignees: HESPERIX SA, The Scripps Research Institute
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
    Publication number: 20210333282
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: August 3, 2020
    Publication date: October 28, 2021
    Applicants: HESPERIX SA, The Scripps Research Institute
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • REPROGRAMMING OF POLYMORPHONUCLEAR LEUKOCYTES
    Publication number: 20210069242
    Abstract: The application is directed a method of treating a cancer in subject by administering to the subject a therapeutically effective amount of polymorphonuclear leukocytes genetically modified to express a recombinant chimeric antigen receptor (CAR) or T cell receptor (TCR). Further provided are modified polymorphonuclear leukocytes and related compositions for use in such methods.
    Type: Application
    Filed: April 17, 2020
    Publication date: March 11, 2021
    Inventors: Dmitry Dmitrievich GENKIN, Alexey Vyacheslavovich Stepanov, Michael Vladimirovich Dubina, Alexey Alexandrovich Bogdanov, Alexander Gabibovich Gabibov
  • ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
    Publication number: 20200400676
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: August 3, 2020
    Publication date: December 24, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Shemyakin-Ovchinnikov institute of Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
    Publication number: 20200363420
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: August 3, 2020
    Publication date: November 19, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Shemyakin-Ovchinnikov institute of Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • ARTICLES AND METHODS DIRECTED TO PERSONALIZED THERAPY OF CANCER
    Publication number: 20200271657
    Abstract: Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
    Type: Application
    Filed: October 4, 2018
    Publication date: August 27, 2020
    Applicants: OPKO Pharmaceuticals, LLC, The Scripps Research Institute, Bioorganic Chemistry, Russian Academy of Sciences, PJSC Pharmsynthez
    Inventors: Alexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Richard A. Lerner, Alexey Anatolievich Belogurov, Alexander Gabibovich Gabibov, Jia Xie
  • METHOD TO IMPROVE SAFETY AND EFFICACY OF ANTI-CANCER THERAPY
    Publication number: 20200188493
    Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.
    Type: Application
    Filed: February 20, 2020
    Publication date: June 18, 2020
    Applicant: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich TETS, Viktor Veniaminovich TETS
  • Method to improve safety and efficacy of anti-cancer therapy
    Patent number: 10617743
    Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: April 14, 2020
    Assignee: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WHICH HAS A DEOXYRIBONUCLEASE (DNase) ACTIVITY
    Publication number: 20190241908
    Abstract: The invention relates to the liver-specific delivery and/or expression of an enzyme which has a deoxyribonuclease (DNase) activity for enhanced clearance of cell free DNA (cfDNA) accumulated in hepatic porto-sinusoidal circulation and the use of such liver-specific delivery and/or expression for treatment of various diseases and conditions, including cancer and neurodegeneration.
    Type: Application
    Filed: January 15, 2019
    Publication date: August 8, 2019
    Applicant: CLS THERAPEUTICS LIMITED
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • EXTRACELLULAR DNA AS A THERAPEUTIC TARGET IN NEURODEGENERATION
    Publication number: 20180360925
    Abstract: The invention relates to the use of deoxyribonuclease (DNase) enzyme for inhibiting progression and for prevention and treatment of neurodegeneration.
    Type: Application
    Filed: May 11, 2016
    Publication date: December 20, 2018
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Vitorovich TETS, Viktor Veniaminovich TETS
  • METHOD TO IMPROVE SAFETY AND EFFICACY OF ANTI-CANCER THERAPY
    Publication number: 20180071370
    Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.
    Type: Application
    Filed: June 19, 2015
    Publication date: March 15, 2018
    Applicant: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • Method for treating oncological diseases
    Patent number: 9845461
    Abstract: A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: December 19, 2017
    Assignee: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich Genkin, Viktor Veniaminovich Tets, Georgy Viktorovich Tets
  • Method for treating systemic DNA mutation disease
    Patent number: 9770492
    Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 26, 2017
    Assignee: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich Genkin, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • METHOD TO IMPROVE SAFETY AND EFFICACY OF ANTI-CANCER THERAPY
    Publication number: 20170100463
    Abstract: The invention relates to the use of a deoxyribonuclease (DNase) enzyme for prevention or amelioration of toxicity associated with various cytostatic and/or cytotoxic chemotherapeutic compounds and radiation therapy.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Applicant: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets
  • METHOD FOR TREATING SYSTEMIC DNA MUTATION DISEASE
    Publication number: 20170056482
    Abstract: The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient.
    Type: Application
    Filed: October 6, 2016
    Publication date: March 2, 2017
    Applicant: CLS Therapeutics Limited
    Inventors: Dmitry Dmitrievich GENKIN, Georgy Viktorovich Tets, Viktor Veniaminovich Tets